Skip to main content

Site notifications

STAQUIS (Pfizer Australia Pty Ltd)

Product name
STAQUIS
Date registered
Evaluation commenced
Decision date
Approval time
249 working days (255)
Active ingredients
crisaborole
Registration type
NCE/NBE
Indication

STAQUIS (2% w/w ointment) is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.

Help us improve the Therapeutic Goods Administration site